Artelo Biosciences, Inc.
SOL Holdings
42274
Artelo Biosciences — Solana-Centric Treasury Strategy in Biopharma
Artelo Biosciences, Inc. (Nasdaq: ARTL) is a clinical-stage
biopharmaceutical company integrating a Solana-focused corporate
treasury strategy alongside its therapeutics pipeline. The company
intends to allocate a portion of capital to acquire and stake SOL under
institutional-grade custody, with governance- and risk-managed
deployment approved by its Board. The stated objectives are to diversify
the balance sheet, generate on-chain staking rewards, and align
treasury management with a high-performance blockchain ecosystem. Artelo
has engaged a seasoned Solana technologist as a technical partner and
selected a specialized provider to support secure storage, staking, and
potential DeFi execution. Progress is communicated via press releases
and investor relations updates.
Artelo
is building a SOL treasury with disciplined, staged allocations,
institutional custody, and validator staking to generate yield, aiming
to complement core biopharma operations while maintaining transparent
Recent Developments
- Aug 5, 2025: Solana holdings increased by 40607.00 SOL to 42274 SOL with cost basis of $7.4M (SOL @ $196.03), stock price $10.45
- Jun 26, 2025: Solana holdings increased by 1667.00 SOL to 1667 SOL with cost basis of $250K (SOL @ $150.00), stock price $5.82
Balance Sheet History
